Globalt Udbrugs- og Registerdatabase for Forbedret Bevaring af Donorpankreas (GUARDIAN-PANCREAS)
Globalt Udnyttelses- og Registerdatabase for Forbedret Konservering af Donorpancreas (GUARDIAN-PANCREAS)
The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving pancreas transplants using donor pancreata transported via the PancreasPak system. These results will be compared to standard of care outcomes, as well as other preservation methods.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
GUARDIAN-PANCREAS is a post-market, observational registry of adult transplant recipient patients whose donor pancreas was preserved and transported within the PancreasPak. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.
About 1000 subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 15 clinical sites.
Candidates that fit the eligibility criteria and have had their donor pancreas transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Amanda Schreiner
- Telefonnummer: 22 781-428-4153
- E-mail: aschreiner@paragonixtechnologies.com
Undersøgelse Kontakt Backup
- Navn: Julia Hersum
- Telefonnummer: 4 781-428-4153
- E-mail: julia@paragonixtechnologies.com
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients who have received a pancreas transplant at centers that use the PancreasPak device.
Beskrivelse
Inclusion Criteria:
• Adult or pediatric recipients of pancreas alone, simultaneous pancreas-kidney, or pancreas after kidney transplant
Exclusion Criteria:
- Donor pancreata that do not meet institutional clinical requirements for transplantation
- Simultaneous pancreas-kidney transplant recipients who received donor organs from multiple donors
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
PancreasPak patient
Patients whose donor pancreas was transported with the PancreasPak device. |
The PancreasPak Donor Preservation System is a FDA cleared and CE-marked medical device intended to be used for the static hypothermic preservation of donor pancreata during transportation and eventual transplantation using cold preservation solutions indicated for use in donor pancreata transplantation. The intended organ preservation time for the PancreasPak system is up to 21 hours. |
|
Standard method patients
Patients whose donor pancreas was transported with a method other than the PancreasPak device. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Graft dysfunction
Tidsramme: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience graft dysfunction post-transplant. |
Post-transplant through 1 year post-transplant
|
|
Pancreatitis
Tidsramme: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience pancreatitis post-transplant. |
Post-transplant through 1 year post-transplant
|
|
Primary Non-Function
Tidsramme: Post-transplant through 7 days post-transplant
|
The percentage of subjects in each cohort who primary non-function post transplantation. |
Post-transplant through 7 days post-transplant
|
|
Length of Hospital Stay
Tidsramme: 1 year
|
How many days the patients stays in the hospital post-transplant. |
1 year
|
|
Surgical Complications
Tidsramme: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience surgical complications. |
Post-transplant through 1 year post-transplant
|
|
Insulin Dependence
Tidsramme: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience insulin dependence post-transplant. |
Post-transplant through 1 year post-transplant
|
|
Graft Failure
Tidsramme: Post-transplant through 1 year post
|
The percentage of subjects in each cohort who develop graft failure post-transplant. |
Post-transplant through 1 year post
|
|
Survival
Tidsramme: Post-transplant through 1 year post
|
The percentage of subjects in each cohort who survive through 1 year post-transplant. |
Post-transplant through 1 year post
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Length of ICU Stay
Tidsramme: 1 year
|
How many days the patient stayed in the ICU post-transplant. |
1 year
|
|
Interventions for Anastomotic Complications
Tidsramme: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who required interventions due to anastomotic complications. |
Post-transplant through 1 year post-transplant
|
|
Intervention for Vascular Complications
Tidsramme: Post-transplant through 1 year-post transplant
|
The percentage of subjects in each cohort who required interventions due to vascular complications. |
Post-transplant through 1 year-post transplant
|
|
Medications
Tidsramme: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who required the use of various medications. |
Post-transplant through 1 year post-transplant
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PGX-008
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .